



INVESTOR PRESENTATION

DISRUPTING THE VARICOSE VEIN MARKET
WITH **SONOVEIN®**

November 2024

EXECUTIVE SUMMARY

- **Theraclion's disruptive approach to varicose vein treatment:** SONOVEIN® is totally non invasive
- **Huge market:** varicose veins affect 1 in 3 adults
- **Proven technology:** 90% to 100% efficacy*, zero serious adverse event, 2,700+ veins treated
- **2023-2024 focus on R&D:** to accelerate the development of a competitive product and FDA approval
- **From R&D to market launch:** commercial effort from 2025 to accelerate SONOVEIN's market access
- **Strategy:** focus on US and Europe with a pay-per-use business model and opportunistic sales elsewhere
- **Financials:** from 2025, positive impact on revenues from commercial acceleration.

* Scientific papers and presentations in medical congresses


VARICOSE VEINS: A WIDESPREAD CONDITION

WHAT ARE VARICOSE VEINS?

Varicose veins are swollen, twisted subcutaneous veins of the lower leg


Inadequacy of the valves results in reflux of blood in the veins

ONE IN THREE ADULTS



31% of adults aged 18 to 64 are affected by varicose veins

Source: Maurins et al., 2008



Source: Austin Vein Specialists

A DISRUPTIVE TREATMENT FOR VARICOSE VEINS

Two main current methods...

STRIPPING
INVASIVE ++



Surgery*

ENDOVENOUS
INVASIVE +



Laser, Radiofrequency, Glue**

... manual, stressful and risky

- Anesthesia
- Surgery
- Sterile space needed
- Potential serious adverse events
- Manual procedure

**NO
SURGERY
NEEDED**

SONOVEIN®
VERY LOW RISK



**NO
INCISION**

NON INVASIVE

- No serious adverse event to date
- Robotic driven, live monitoring
- Quick walk-in walk-out procedure
- One operator only
- Data collection-capability & AI automation potential

VARICOSE VEINS: A MULTIBILLION \$ MARKET POTENTIAL

ALIGNED WITH CURRENT MARKET TRENDS



\$13B

Current medical costs for varicose vein treatments worldwide



5M+

Annual addressable procedures



Up to 50%

Sonovein device cost per procedure

vs:

- Stripping: 1-2%
- Endovenous: 10-15%




SIGNIFICANT GROWTH DRIVERS AND OPPORTUNITIES

- **6,5% annual growth** in varicose veins patients driven by
① Age ② Obesity ③ Lifestyle

- **54% of undiagnosed patients** in industrialized countries
- Largely **unmet medical need** in emerging countries + China

- **50% of people afraid of surgery**
→ untapped patient pool for Sonovein

SONOVEIN[®], A NEW ROBOTIC SOLUTION



INTELLECTUAL PROPERTY

Active patents : 134 granted, 170 filed, 23 families in HIFU procedure safety & efficacy, system design and application

BASED ON THERMAL ABLATION


FROM PRINCIPLE...

ULTRASOUND: FOCUSED ACOUSTIC WAVES

- A treatment from outside: no incision
- High Intensity Focused Ultrasound (HIFU)


Spherical transducer

Concentrates ultrasound wave to the focal point



... TO APPLICATION

THERACLION'S SONOVEIN FOR VARICOSE VEINS



- Step by step treatment, **moving along** the vein and heating it
- **Robot-driven** movements
- Real-time **ultrasound visualization** and control

SONOVEIN[®], NOW A MATURE DEVICE

EFFECTIVE AND SAFE TREATMENT OF VARICOSE VEINS



OVER 2,700 VEIN TREATMENTS TO DATE

- 90% to 100% efficacy*
- 0 severe adverse event**
- Treatment duration ≤1h



+ 18 SITES IN OPERATION IN 12 COUNTRIES

- Top centers at more than 100 treatments/year



+ CE MARKING OBTAINED IN 2019

Latest generation of Sonovein in the process to obtain the new MDR CE marking



+ FDA FEASIBILITY STUDY FINALISED

FDA Pivotal study: started in 2023, treatments finished in June 2024

//

*The results are as good - if not a little bit **better** - than some of the results with the more traditional technologies. **95%** of patients had a successful healing of the abnormal vein. All patients felt better.*


***SONOVEIN really is the next evolution** of a completely non-invasive, transcutaneous way of treating vein diseases. //*

Dr Steve Elias - January 2023

(FDA first US trial – principal investigator)

SONOVEIN[®], NOW A MATURE DEVICE

TIME TO GO TO MARKET



GO TO MARKET ACCELERATION

TWO DIFFERENT BUSINESS MODELS

RECURRING REVENUES YEAR ON YEAR VERSUS 1-OFF REVENUES

DIRECT SALES*

Capital equipment
+
Consumables
+
Service


CHINA AND ROW

PAY-PER-USE

Paying consumables
only

(w/ monthly min. quantity)

EUROPE AND USA




OUR CONSUMABLE

Single-use **EPack™**:
ensures cooling and
coupling

* To medical centers, hospitals, clinics

US MARKET: A MAIN PRIORITY

FDA STUDY COMPLETED



PIVOTAL STUDY

- Main focus during the past two years
- Dedication of most resources
- Treatments finalisation: time to go to market


MARKET

- Largest varicose vein market in the world: 45%
- High price market
- Homogenous access to reimbursement
- Strategic partnerships option

US TARGETS

- At start
 - 300 high volume medical centers at 200 treatments/year at \$1.5k to \$3k each
 - Revenue: \$90-180m/year
- Revenue at maturity: \$400m-\$500m/year

GROWTH ROADMAP AND KEY MILESTONES




THERACLION

SHAREHOLDING STRUCTURE

SHAREHOLDERS

(as of December 31st, 2023)



ALTHE

FURUI (300049:CH): GENUINE STRATEGIC PARTNERSHIP

- Theraclion's investor since 2016
- China JV created in 2017
- **Replication of Echosens' Success:**
 - **Echosens (France):** +/-300 employees, global leader in non-invasive liver diagnostics.
 - **Furui lead development in China,** supports R&D in France and global commercial deployment.
 - Echosens China is a **key contributor to Echosens Global P&L.**

A SHARP AND ENGAGED MANAGEMENT TEAM

A SKILLED & DYNAMIC NEW LEADERSHIP TEAM



Martin Deterre, PhD
CEO
15y. exp
Livanova, Pixium
M.I.T.,
Polytechnique
*Theraclion since Dec.
2020 as CTO
CEO since May 2023*



Christophe Lamboeuf
CFO
30+y. exp
Mauna Kea, Intrasure, Skytech, GE, etc.
Theraclion since Sept. 2024

... SUPPORTED BY A STABLE AND EXPERIENCED TEAM



Michel Nuta, MD
Chief Medical Officer
30+y. exp, ex-VNUS
THC since Jan. 2013



Jérémie Anquez, PhD
Chief Scientific Officer
15+y. exp
Telecom ParisTech
THC since June 2010



Vivien Jourdain
VP QARA
10y. exp
Mauna Kea
THC since Oct. 2015



Gaylord Tallec, PhD
VP Operations
15y. exp
CEA, lifesearch
THC since Sept. 2016



Marie Berne
Head of Marketing & customers relations
10y. exp
Dior, Figaret, EM Lyon
THC since Oct. 2021



29 employees based
in Paris, France
**23 engineers, 6 PhD,
1 PharmD, 1 MD**

AN EXPERIENCED AND SUPPORTIVE BOARD

AN EXPERIENCED CHAIRMAN



Yann Duchesne
Chairman of the board
McKinsey 20y.
Private Equity 13y.
Theraclion since 2022

WITH HIGHLY QUALIFIED BOARD MEMBERS



Ari S. Kellen, MD
Board Member
US-based, Ex. McKinsey,
Experienced operating executive
and advisor in US healthcare
THC since 2019



Shawn Langer, MD
Board Member
US-based, Ex. senior partner
McKinsey, 20+y. of healthcare
industry experience
THC since 2019



Cédric Bellanger
Board Member
CBML / Augusta
Real Estate & Capital Investment
fund manager
THC since 2022



Claude Lenoir
Board Member
Former CEO of Echosens
and Air Liquide Medical
Systems
THC since 2023



Mehdi El Glaoui,
Pharm.D
Board Member
Ex-CEO Lab. Cassenne,
Wyeth, Marjorelle
THC since 2021



Lijuan Deng
Board Member
17+y. in healthtech
Board of Echosens, Furui
THC since 2023

SONOVEIN SUCCESS IN VARICOSE VEINS WILL OPEN THE WAY TO OTHER THERAPIES

VARICOSE VEINS

Build platform

Succeed 1st commercial
breakthrough

THYROID NODULES

\$3.6B market
1,800,000 annual thyroid
nodules surgeries WW

Theraclion's
historical market

Latest Vein platform can
disrupt the Thyroid market

BREAST CANCER

\$20B market, strong growth

Huge potential for HIFU
combined with traditional
therapies: immunology or
chemotherapy

Clinical studies ongoing at
University of Virginia with
Theraclion's device

MORE INDICATIONS

Hyperthermia - Possibility
to heat cancer tissue
locally prior to
radiotherapy

Research programs ongoing

Other indications



- **HIFU:** High Intensity Focused Ultrasound is a non-invasive therapeutic technique that uses non-ionizing ultrasonic waves to heat or ablate tissue.
- **Venous reflux or Chronic Venous Insufficiency (CVI):** occurs when veins no longer circulate blood properly. It often affects the leg veins, causing blood to pool and leading to swelling and discomfort.
- **Serious Adverse Events (SAE):** an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
- **CEAP classification:** the CEAP (Clinical-Etiology-Anatomy-Pathophysiology) classification is an internationally accepted standard for describing patients with chronic venous disorders
- **FDA:** Food and Drug Administration

DISCLAIMER

This presentation does not constitute an offer to sell or a solicitation of a THERACLION share purchase offer.

Some information in this document may include projections and forecasts. THERACLION believes that these forward-looking statements are based on reasonable assumptions as at the date of this document, which are subject to numerous risks and uncertainties. As a result, the numbers and ratings provided may differ significantly from the projected figures. THERACLION neither undertakes nor has the obligation to update the forward-looking information contained in this presentation to reflect any unforeseen event or circumstance occurring after the date of this presentation.

The information contained in this document has been selected by the Group's General Management to present THERACLION and THERACLION's results. This document has not been independently verified. THERACLION makes no commitment as to the accuracy or completeness of this information. None of THERACLION's representatives can be held responsible for any loss resulting from the use of this presentation or its content.

Under no circumstances will THERACLION assume any responsibility for any investment or other decisions made on the basis of the information provided in this presentation. Readers are advised to review the company's financial information and the applicable AMF filings of the company before making any investment or other decision.

Thank you !!

**FOLLOW US ON
LINKEDIN FOR
UPDATES**



bit.ly/3KYQKJD

THERACLION

244 av. Pierre Brossolette
92240 Malakoff


T +33 1 55 48 90 70

E contact@theraclion.com

APPENDICES

VARICOSE VEINS: A WIDESPREAD CONDITION


A STRONG MEDICAL NEED



THE VENOUS SYSTEM

Superficial compartment
Cosmetic impact

Saphenous compartment
Often incompetent



Deep venous system
Main venous stream

Treatment options

SONOVEIN

Sclerotherapy – mini-invasive

Endovenous – mini-invasive

Stripping – invasive

PROOF OF CONCEPT AND PRODUCT FINE-TUNING IN EUROPE THANKS TO STRONG KOL* PARTNERSHIPS

PRODUCT REFINEMENT WITH KOL*

- Fine-tuning product, protocols, and business offering
- Real-life field feedback and product needs collection
- Diversity of market practices addressed
- Data collection for next AI development

PROOF OF CONCEPT TODAY- ONGOING RAMP UP

- Tier-1 sites at 100 or 150 treatments per year already
- Commercial relationships and existing recurring revenue
- Start of reimbursement in some countries (Spain, Italy)

INTERNATIONAL AWARENESS

- Sonovein's promotion by KOL* in some of the largest European countries: Italy, France, Spain and the UK
- 50+ conferences by 15 KOL and 7 reference scientific papers
H1 2024: 13 presentations in 9 int. conferences in 7 countries

*: Key Opinion Leaders



OPPORTUNITIES IN CHINA AND REST OF THE WORLD



MARKET

- Largest potential varicose vein market in Asia
- Underserved market that could move directly to Sonovein's non-invasive solution to reach so far untreated patients

CHINESE MARKET PATH & PARTNERSHIP WITH FURUI

- Domestic product development and market access via Furui
- Global manufacturing
- JV's products sold only in China

NEXT MILESTONES

- Joint-Venture with Furui
- Prototyping
- Registration
- Clinical trial start (1-2 years)

MARKET

- Inbound demand from some countries (Middle East, Eastern Europe) and China (Furui)
- Business Model: Sonovein acquisition
- Large untapped market, not yet quantified

MARKET PATH

- Opportunistic sales of Sonovein
- Short term focus : Middle East, Eastern Europe and China
- Longer term focus: Latin America, Rest of Asia (India, etc)

ROW TARGETS

- ±90 Sonovein sold in 2030
- Consumables sales attached to the machines

ROW

Clinical Results – Overview

| Type of Result | Author | Efficacy Results | Title | Location / Reference |
|-----------------------|---|---|---|---|
| Publication | Dr. Elias Englewood, USA | First Ever SONOVEIN Chapter written in an American Reference Book | Chapter 45: High Intensity Focused Ultrasound (HIFU) for chronic venous disease | Handbook of Venous and Lymphatic Disorders, Gloviczki, USA, 2024 |
| Congress Presentation | Dr. Casoni Parma, Italy | 360 Limbs Treated / 78% at 1 Week / 93% at 6 Months / 95% at 12 Months / 96% at 24 Months | High Intensity Focused Ultrasound in treating Great Saphenous Vein: perioperative, 1 & 2-years outcomes | International Congress of Phlebology, Bologna, Italy, 2024 |
| Publication | Dr. Casoni Parma, Italy | 1-Year Results on 188 Limbs : 98,3% Occlusion | High intensity focused ultrasound in treating great saphenous vein incompetence... | Phlebology, 2024 |
| Congress Presentation | Dr. Carvajal Marbella, Spain | 90% Occlusion Rate on 205 Veins | High Intensity Focused Ultrasound (HIFU) | Vein In Venice, Venice, Italy, 2024 |
| Congress Presentation | Dr. Stalnikiewicz Lille, France | Occlusion Rate is Close if not 100% on GSVs & 70 – 80% on Perforators | High Intensity Focused Ultrasound (HIFU): short mid-term results | |
| Publication | Dr. Reyero, Dr. Lamoca Madrid, Spain | 3-Year Results on 119 Patients: 94,1% Occlusion Rate | Treatment with Localized High Intensity Ultrasound ... 3-Year Results | Angiologia, Spain, 2023 |
| Congress Presentation | Dr. Steinbacher Melk, Austria | 100% Occlusion Rate on 23 Veins with Sonovein HD No Side Effects | First Experience with Sonovein HD | AVF 2023, San Antonio, Texas, 2023 |
| Congress Presentation | Pr. Strejcek Prague, Czech Republic | 90,2% Occlusion Rate on 41 Patients | Overview of a Pool of 41 Veins Treated in Routine Activity Over a 1-Month Period | AVF & UIP, San Antonio & Miami, 2023 |
| Publication | Pr. Strejcek Prague, Czech Republic | First Ever SONOVEIN Chapter Written in a European Reference Book | Chapter 15 : Ecotherapy (HIFU) | Manual of Ambulatory Phlebology, Frullini, Italy, 2023 |

R&D: FINALIZING BLOCKBUSTER PRODUCT READY IN 1.5 YEARS

ACCELERATING GO TO MARKET WHILE FINE-TUNING THE SONOVEIN



ACCELERATE TREATMENT TIME

From: 45 min to 1h

Down to: 30min



IMPROVE EASE OF USE

From: a device for an ultrasound trained medical doctor

Down to: an AI-guided, intuitive device for a non-specialist



INCREASE ADDRESSABLE PATIENT POPULATION

From: mostly great saphenous* vein

Up to: more types of veins, larger, deeper



KEY ENABLERS

AI

ACOUSTICS

ROBOTICS

CLINICAL PRACTICE

2024 Half Year P&L : Net loss of 2,4 M€, down 4,6% over LY

| En K€ | H1 2024 | H1 2023 | V% |
|---------------------------------|----------------|----------------|---------------|
| Sales | 442 | 981 | (55%) |
| Other Income | 149 | 0 | |
| Total Operating Revenues | 591 | 981 | (40%) |
| Cost of Sales | 171 | 532 | (68%) |
| External operating expenses | 1 640 | 1 115 | 47% |
| Comp & Ben. | 1 662 | 1 957 | (15%) |
| Other operating expenses | 106 | 556 | (81%) |
| Total operating expenses | 3 578 | 4 160 | (14%) |
| Operating profit | (2 988) | (3 179) | (6%) |
| Financial revenue/ (expense) | 84 | (65) | (229%) |
| non recurring profit / (loss) | 16 | 263 | (94%) |
| R&D tax credit | (525) | (504) | 4% |
| Net Profit / (Loss) | (2 364) | (2 476) | (4,6%) |

Gross Margin up to 61% vs 46% last year du to a favourable product mix with consumables and services representing 75,3% of the total sales compared to 64,3% in 2023.

Increase of 0,5 M€ of Operating expenses

- Clinical studies & R&D
- Impact of negative rentals in 2023
- Legal fees down

Salaries are down 15%

Provision for risk booked in 2023:

- stocks depreciation (Echopulse)
- accruals for risk
- bad debts

Interests gain on long term bank savings in 2024

- In 2023: includes Coface/BPI insurance coverage & subsidies

2024 Half Year BALANCE SHEET – Improved Working Capital

| K€ | H1 2024 | FY 2023 | Var. |
|--|---------------|---------------|----------------|
| Non-current assets | 2 479 | 2 542 | (63) |
| Including intangible assets | 1 178 | 1 225 | |
| Including tangible assets | 97 | 106 | |
| Of which non-current financial assets | 1 205 | 1 211 | |
| Current assets | 12 383 | 16 122 | (3 739) |
| Inventory | 3 171 | 3 055 | |
| Cash and cash equivalent | 5 898 | 7 815 | |
| Other assets | 3 313 | 5 252 | |
| Total Asset | 14 862 | 18 664 | (3 802) |
| Equity | 3 284 | 5 777 | |
| Non current liabilities | 6 290 | 6 290 | |
| Including advances from BPI | 6 290 | 6 290 | |
| Current liabilities | 5 288 | 6 597 | (1 309) |
| Incl. Accruals for Risk & Curr. Exposure | 246 | 215 | |
| Incl. Loans (PGE) | 1 620 | 1 947 | |
| Total Liabilities | 14 862 | 18 664 | (3 802) |

- **Accounts receivables** down 2,2M€
+2M€ licenses in 2023 paid in 2024 and
300K reduction of other A/R.

PUBLICATIONS & PRESENTATIONS ABOUT SONOVEIN®

REFERENCE PUBLICATIONS

| SOURCE | AUTHOR | TITLE AND REFERENCE | YEAR |
|--|-----------------------------|--|------|
| Phlebology Journal | Prof. Paolo Casoni | Action of high intensity focused ultrasound (HIFU) ablation on the venous wall: Histopathological analysis, insights, and perspectives DOI: https://doi.org/10.1177/02683555241297215 | 2024 |
| Handbook of Venous and Lymphatic Disorders | Dr. Steve Elias | Chapter 45: High Intensity Focused Ultrasound (HIFU) for chronic venous disease DOI: https://doi.org/10.1201/9781003328971 | 2024 |
| Phlebology Journal | Prof. Paolo Casoni | High Intensity Focused Ultrasound in treating great saphenous vein incompetence: Perioperative and 1-year outcomes DOI: 10.1177/02683555241243161 | 2024 |
| Société Française de Phlébologie | Dr. Guillaume Stalnikiewicz | Non-invasive thermal treatment of great saphenous varicose veins using ultrasound therapy Update of efficacy and safety data based on a series of cases Link : https://www.phlebo-online.org/traitements-thermiques-non-invasifs-des-varices-grandes-saphenes-par-echotherapie | 2023 |
| Clinical, Cosmetic and Investigational Dermatology | Prof. Mark Whiteley | Current Best Practice in Management of Varicose Veins DOI: 10.2147/CCID.S294990 | 2022 |
| EJVES Vascular Forum | Dr. Alfred Obermayer | Extracorporeal Treatment with High Intensity Focused Ultrasound of an Incompetent Perforating Vein in a Patient with Active Venous Ulcers DOI: 10.1016/j.ejvsf.2020.11.005 | 2021 |
| Karl Landsteiner Gesellschaft | Dr. Alfred Obermayer | Weltpremiere : Perkutaner Verschluss von insuffizienten Venen mittels Ultraschall (HIFU) [English] World premiere: Percutaneous closure of insufficient veins using ultrasound (HIFU) Link: https://www.karl-landsteiner.at/pdf/LT/Vortrag%2011.%20Landsteiner%20Tag%202020%20Obermayer.pdf | 2020 |
| Current Medical Research and Opinion | Prof. Mark Whiteley | High intensity focused ultrasound (HIFU) for the treatment of varicose veins and venous leg ulcers - a new non-invasive procedure and a potentially disruptive technology DOI: 10.1080/03007995.2019.1699518 | 2019 |

2024 PRESENTATIONS: 18 events, 10 speakers, 8 countries *(to date)*

| EVENT | SPEAKER | TITLE | LOCATION | DATE |
|---|---|---|--------------------|----------------------------|
| 38th GMS Vascular Medicine Symposium Berlin | Prof. Jaroslav Strejček | HIFU - technical development status and current data situation | Berlin, GERMANY | COMING UP FALL 2024 |
| University of Siena Lecture | Prof. Paolo Casoni | HIFU for varicose veins | Sienna, ITALY | COMING UP FALL 2024 |
| VEITHsymposium | Dr. Steve Elias | HIFU for varicose veins | New York, US | COMING UP NOVEMBER 2024 |
| Venous Symposium Europe | Dr. Antonios Gasparis | HIFU for varicose veins | Athens, GREECE | COMING UP OCTOBER 2024 |
| Federico II University of Naples Lecture | Prof. Paolo Casoni | HIFU for varicose veins | Naples, ITALY | COMING UP OCTOBER 2024 |
| Congresso Internazionale di Flebologia | Prof. Paolo Casoni | High-intensity focused ultrasound in treating great saphenous vein incompetence: perioperative and 1 and 2-years outcomes | Bologna, ITALY | OCTOBER 2024 |
| | Dr. Emanuele Nanni | Action of High Intensity Ultrasound (HIFU) on the vein wall: histopathological analysis | | |
| Congrès de la Société Française de Médecine Vasculaire (SFMV) | Dr. Guillaume Stalnikiewicz | HIFU for varicose veins | Dijon, FRANCE | SEPTEMBER 2024 |
| European Venous Forum (EVF) Meeting | Dr. Matteo Pizzamiglio | High Intensity Focused Ultrasound in treating great saphenous vein incompetence: perioperative and 1-year outcomes | Athens, GREECE | JUNE 2024 |
| Benelux Society of Phlebology Congress | Prof. Mark Whiteley | Percutaneous ablation using high-intensity focused ultrasound | Genk, BELGIUM | JUNE 2024 |
| | Dr. Luis Riera del Moral | High-intensity focused ultrasound | Burgos, SPAIN | JUNE 2024 |

2024 PRESENTATIONS: 18 events, 10 speakers, 8 countries *(to date)*

| EVENT | SPEAKER | TITLE | LOCATION | DATE |
|--|------------------------------|--|---------------------|---------------|
| Sorbonne Lecture | Dr. Guillaume Stalnikiewicz | HIFU for varicose veins | Paris, FRANCE | JUNE 2024 |
| Venous Symposium | Dr. Steve Elias | High Intensity Focused Ultrasound: Multicenter Trial | New York, US | MAY 2024 |
| Canadian Society of Phlebology Congress | Dr. Emanuele Nanni | HIFU: How it works and outcomes | Montreal, CANADA | MAY 2024 |
| College of Phlebology UK Masterclass | Prof. Mark Whiteley | Mastering Venous Insufficiency with HIFU: The Ultimate Guide to Sonovein Echotherapy for Optimal Results | Guildford, UK | MAY 2024 |
| | Dr. Guillaume Stalnikiewicz | HIFU: What it is, What it makes, and... What it takes! | | |
| | Prof. Luis Izquierdo Lamoca | HIFU Efficiency in Leak Point Closure in the Chiva Procedure Description and 4 Years Result | | |
| Vein in Venice Symposium | Dr. Guillaume Stalnikiewicz | High Intensity Focused Ultrasound (HIFU): Short- and mid-term results | Venice, ITALY | APRIL 2024 |
| | Dr. Ruben Rodriguez Carvajal | High Intensity Focused Ultrasound | | |
| Chiesi Farmaceutici Phlebological Meeting | Prof. Paolo Casoni | Role of high-intensity focused ultrasound intensity: experience at 2 years | Parma, ITALY | APRIL 2024 |
| AFI DAY by the Italian Association of Phlebology | Prof. Paolo Casoni | Role of high-intensity focused ultrasound intensity: experience at 2 years | Perugia, ITALY | APRIL 2024 |
| Italian Society of Aesthetic Medicine and Surgery (SIES) | Prof. Paolo Casoni | Role of high-intensity focused ultrasound intensity: experience at 2 years | Bologna, ITALY | FEBRUARY 2024 |
| Find Your Algorithm (FYA) Congress | Prof. Mark Whiteley | Upcoming treatment in venous reflux | London, UK | JANUARY 2024 |

2023 PRESENTATIONS: 12 events, 10 speakers, 7 countries (part 1)

| EVENT | SPEAKER | TITLE | LOCATION | DATE |
|---|-----------------------------|---|--------------------------|----------------|
| International Meeting on Aesthetic Phlebology (IMAP) | Prof. Mark Whiteley | New insights into success and failure of Venous Ablation with Sonovein (HIFU) - WINNER OF THE HIROSHI MIYAKE AWARD | Sao Paulo, BRAZIL | DECEMBER 2023 |
| French Society of Phlebology Congress | Dr. Guillaume Stalnikiewicz | Les HIFU sont-ils l'avenir du traitement des varices ? <i>[English] Is HIFU the future of varicose vein treatment?</i> | Paris, FRANCE | DECEMBER 2023 |
| VEITHsymposium | Dr. Steve Elias | HIFU: What Do We Know And Report - Global Report | New York, US | NOVEMBER 2023 |
| Endovascular Foundation SITE Symposium | Prof. Mark Whiteley | Echotherapy for varicose veins. What have we already learnt in last two years? Recorded case - Echotherapy with Sonovein. Advances to date | Barcelona, SPAIN | OCTOBER 2023 |
| | Dr. Luis Izquierdo Lamoca | Spanish experience with echotherapy | | |
| VIVA VEINS | Dr. Steve Elias | SONOVEIN technology presentation | Las Vegas, US | OCTOBER 2023 |
| International Union of Phlebology (UIP) & American Venous Lymphatic Society (AVLS) Congress | Prof. Paolo Casoni | Action of High Intensity Focused Ultrasound (HIFU) on the Venous Wall: Histopathological Analysis | Miami, US | SEPTEMBER 2023 |
| | Prof. Jaroslav Strejček | Innovations in Chronic Venous Disease Treatment | | |
| | Dr. Steve Elias | Other Ablation Techniques Emerging Technology | | |
| | | Emerging Technologies: High Intensity Focused Ultrasound - Sonovein | | |
| | Dr. Ferdinand Steinbacher | First 28 patients with Sonovein HD | | |

2023 PRESENTATIONS: 12 events, 10 speakers, 7 countries *(part 2)*

| EVENT | SPEAKER | TITLE | LOCATION | DATE |
|---|------------------------------|---|-----------------|---------------|
| Egyptian Venous Forum | Dr. Ruben Rodriguez Carvajal | High Intensity Focused Ultrasound | Cairo, EGYPT | JULY 2023 |
| Venous Symposium | Dr. Steve Elias | HIFU: What Do We Know And Report | New York, US | MAY 2023 |
| Leading Innovative Vascular Education (LIVE) Venous Symposium (VS) European Chapter | Dr. Antonios Gasparis | Novel Technologies in Superficial Venous Disease Management | Corfu, GREECE | MAY 2023 |
| European Venous Forum (EVF) Meeting | Dr. Emanuele Nanni | Action of HIFU on the venous wall: Histopathological analysis | Berlin, GERMANY | JUNE 2023 |
| Symposium on Therapeutic Ultrasound | Bjoern Gerold, PhD | CURE-OP: Thermometry for Hyperthermia Treatments | Lyon, FRANCE | APRIL 2023 |
| American Venous Forum (AVF) Congress | Dr. Antonios Gasparis | First In US Sonovein Trial: Final Results | San Antonio, US | FEBRUARY 2023 |
| | Dr. Steve Elias | | | |
| | Dr. Ferdinand Steinbacher | First Experience with Sonovein HD | | |

2022 PRESENTATIONS: 10 events, 8 speakers, 6 countries (part 1)

| EVENT | SPEAKER | TITLE | LOCATION | DATE |
|--|-----------------------------|--|------------------|---------------|
| College of Phlebology UK E-meeting | Prof. Mark Whiteley | Special session dedicated to HIFU | Online UK | DECEMBER 2022 |
| | Prof. Paolo Casoni | What is the HIFU procedure treating varicose veins? | | |
| | Dr. Guillaume Stalnikiewicz | Which patients are the best fit for HIFU procedure? | | |
| | Dr. Teresa Reyero Postigo | Why is Sonovein revolutionary in treating varicose veins? | | |
| French Society of Phlebology | Dr. Guillaume Stalnikiewicz | Traitement non invasif des perforantes incontinentes par échothérapie : série de cas | Paris, FRANCE | DECEMBER 2022 |
| | Dr. Maxime de Deken | | | |
| | Prof. Paolo Casoni | HIFU can change phlebology: the Italian experience in 80 cases | | |
| VEITHsymposium | Prof. Mark Whiteley | Truncal Ablation of the Saphenous Venous System | New York, US | NOVEMBER 2022 |
| Focused Ultrasound Foundation International Symposium 2022 | Dr. Steve Elias | Top-line results from 20 patients treated with SONOVEIN® HD | Rockville, US | OCTOBER 2022 |
| | Dr. Ruben R. Carvajal | Preliminary results on 47 patients treated with SONOVEIN® S | | |
| VIVA VEINS | Dr. Steve Elias | First patients treated with SONOVEIN® | Las Vegas, US | OCTOBER 2022 |

2022 PRESENTATIONS: 10 events, 8 speakers, 6 countries (part 2)

| EVENT | SPEAKER | TITLE | LOCATION | DATE |
|---|-----------------------------|---|-------------------------|----------------|
| American Vein & Lymphatic Society (AVLS) | Dr. Steve Elias | HIFU for Great Saphenous Vein Incompetence: First Initial US Expérience and Results | New Orleans, US | OCTOBER 2022 |
| Spanish Society For Surgical Research | Dr. Teresa Reyero Postigo | High Intensity Focused Ultrasound for Varicose Veins | Gijón, SPAIN | SEPTEMBER 2022 |
| Congrès de la Société Française de Médecine Vasculaire (SFMV) | Dr. Maxime de Deken | Traitement non-invasif des veines perforantes incontinentes par échothérapie : série de cas | Toulouse, FRANCE | SEPTEMBER 2022 |
| International Union of Phlebology (UIP) Congress | Prof. Mark Whiteley | Thermal, nonthermal or HIFU in 2022 | Istanbul, TURKEY | SEPTEMBER 2022 |
| | Prof. Paolo Casoni | HIFU how ultrasounds can change phlebology: the Italian experience in 80 cases | | |
| | Prof. Jaroslav Strejček | HIFU: a revolutionary step on the way to non-invasive treatment of varicose veins | | |
| | Dr. Teresa Reyero Postigo | HIFU Efficiency in leak point closure in the conservative hemodynamic treatment of venous insufficiency | | |
| Swiss Vein days | Dr. Guillaume Stalnikiewicz | Sonovein treatments results: 95% occlusion rate | Bruderholz, SWITZERLAND | JUNE 2022 |

2021 PRESENTATIONS: 7 events, 3 speakers, 6 countries

| EVENT | SPEAKER | TITLE | LOCATION | DATE |
|---|-------------------------------------|---|------------------------------|--------------------------------|
| VEITHsymposium | Prof. Mark Whiteley | HIFU: Is it ready for Prime Time? Tips, Tricks and Limitations: HIFU | Orlando, US | NOVEMBER 2021 |
| Paris Vascular Insights | Prof. Mark Whiteley | Treatment of saphenous veins with HIFU | Paris, FRANCE | OCTOBER 2021 |
| Egyptian Venous Forum | Prof. Mark Whiteley | Stop surgery and go HIFU for the treatment of varicose veins | Alexandria, EGYPT | OCTOBER 2021 |
| Congresso Internazionale di Flebologia | Prof. Paolo Casoni | HIFU (High Intensity Focused Ultrasound): how ultrasounds can change phlebology: mechanism of action and future indications | Bologna, ITALY | SEPTEMBER 2021 |
| Congrès de la Société Française de Médecine Vasculaire (SFMV) | Dr. Maxime de Deken | Innovation thérapeutique dans la maladie veineuse chronique : premiers résultats de l'échothérapie ou traitement par ultrasons focalisés de haute intensité (HIFU) échoguidés | Cannes, FRANCE | SEPTEMBER 2021 |
| Kazakhstan Venous Forum | Prof. Mark Whiteley | Early results of Sonovein and Sonovein S (High Intensity Focused Ultrasound) treatment of varicose veins | Online KHAZAKHSTAN | MAY 2021 |
| Venous Association of India Conference (VAICON) | Prof. Mark Whiteley | Sonovein and Sonovein S - How I do it | Online INDIA | JANUARY 2021 |

2019-20 PRESENTATIONS: 13 events, 1 speaker, 9 countries

| EVENT | SPEAKER | TITLE | LOCATION | DATE |
|---|-------------------------------------|---|------------------------|-------------------------------|
| 16 th UCCVS | Prof. Mark Whiteley | The Latest and Most Revolutionary Echotherapy Treatment for Varicose Veins and Venous Leg Ulcers: SONOVEIN | Antalya, TURKEY | OCTOBER 2020 |
| International Union of Phlebology (UIP) Webinar | Prof. Mark Whiteley | HIFU - The Good, the Bad and The Ugly | Online | AUGUST 2020 |
| American Vein & Lymphatic Society (AVLS) Congress | Prof. Mark Whiteley | Six months outcomes from high intensity focused Ultrasound (HIFU) closure of incompetent saphenous and perforator veins | Online US | JULY 2020 |
| SBACVES Sociedade | Prof. Mark Whiteley | High Intensity Focused Ultrasound (HIFU) closure of Varicose Veins - Echotherapy (Sonovein) | Online BRAZIL | JULY 2020 |
| EgyVasc Virtual Conference | Prof. Mark Whiteley | Is HIFU the future of Varicose Veins Ablation? | Online EGYPT | JUNE 2020 |
| IMAP X Live 2020 | Prof. Mark Whiteley | Is HIFU the future of Varicose Veins Ablation? | Online BRAZIL | MAY 2020 |
| Sonovein Echotherapy Webinar | Prof. Mark Whiteley | Echotherapy Treatment of Varicose Veins using Sonovein (HIFU) | Online UK | APRIL 2020 |
| Venous Association of India Conference (VAICON) | Prof. Mark Whiteley | Description of a new technique: Sonovein Indications and Results | Mumbai, INDIA | JANUARY 2020 |
| Controversies & Updates in Vascular Surgery (CACVS) | Prof. Mark Whiteley | Description of a new technique the Sonovein: indications, results | Paris, FRANCE | JANUARY 2020 |
| Society Vascular Technologists (SVT) Meeting | Prof. Mark Whiteley | The role of ultrasound and the vascular technologist in High Intensity Focused Ultrasound (HIFU) treatment for venous incompetence - 1ST PRIZE WINNER | Manchester, UK | NOVEMBER 2019 |
| American Vein & Lymphatic Society (AVLS) Congress | Prof. Mark Whiteley | High Intensity Focused Ultrasound (HIFU) in the Treatment of Incompetent Superficial Veins and Perforating Veins: a Report of our Early Experience - 2ND PRIZE WINNER | Phoenix, US | NOVEMBER 2019 |
| Middle East Venous Forum | Prof. Mark Whiteley | Early report of High Intensity Focused Ultrasound (HIFU) in the treatment of varicose veins | Abu Dhabi, UAE | OCTOBER 2019 |
| Northern European Endovenous Forum (NEEF) | Prof. Mark Whiteley | Novel thermal techniques for the treatment of superficial venous reflux - Endovenous Microwave Ablation (EMWA) and High Intensity Focused Ultrasound (HIFU) | Riga, LATVIA | AUGUST 2019 |

**FOLLOW US ON
LINKEDIN FOR
UPDATES**



THERACLION

244 av. Pierre Brossolette
92240 Malakoff

T +33 1 55 48 90 70

E contact@theraclion.com